Fang Ni, Pharm.D.

Fang Ni, Pharm.D.

Chief Business Officer and Interim Chief Financial OfficeratBlack Diamond Therapeutics· In proxies 2022–2023

Pay in FY2023+64% from the year before · Black Diamond Therapeutics stock +56.1% the same year

Fang Ni, Pharm.D. was paid $1.5M in FY2023 (Dec), up 64%. Black Diamond Therapeutics stock rose 56.1% that year.

Pay$100 in the stock at the end of FY21 → $53
Pay is from the Summary Compensation Table of each Black Diamond Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Black Diamond TherapeuticsPublic company · 4 yr
    • Chief Business Officer and Interim Chief Financial Officer2022 – Present · 4 yrStock in role -65%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?